This website contains information on veterinary products based on international registration dossiers and may refer to products that are either not available in your country or are marketed under different trade names.

In addition, the approved indications as well as the safety and efficacy data for a specific product may be different depending on local registrations and approvals.

For more information, read the product labeling that applies to your country or contact your local Animal Health representative.
EXIT
ILT has become a ‘serious problem’
Learn More
International Poultry Expo, Jan. 28-30, 2014 Atlanta, USA

See video highlights of the ND seminar held at the International Poultry Expo!

more

Why INNOVAX®?

Watch the video

Infectious laryngotracheitis (ILT), Newcastle disease (ND) and Marek’s disease (MD) can significantly impair performance and, if left uncontrolled, wipe out entire flocks.

Traditional vaccines made with killed or attenuated live viruses are available to aid in the prevention of the highly contagious ILT and ND. Trouble is, they often need to be administered at different times to ensure lifelong protection, and worse yet, some vaccines can cause costly reactions that hurt flock performance and profitability.

To address this issue, scientists at Merck Animal Health developed the INNOVAX line of recombinant vaccines, which can be conveniently administered to chickens in one dose at the hatchery — either in ovo to 18-day chicken embryos or by subcutaneous injection at 1 day of age. The vaccines help prevent their target diseases with no costly reactions.

The foundation of the INNOVAX vaccine line is the herpesvirus of turkey (HVT), known to be safe for chickens. HVT not only helps prevent MD, it also acts as a carrier for the ND or ILT antigens that stimulate immunity. This contrasts with traditional vaccines, which introduce attenuated live ND and ILT viruses to help stimulate immunity.